{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T12:23:16Z","timestamp":1773922996793,"version":"3.50.1"},"reference-count":43,"publisher":"American Academy of Pediatrics (AAP)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2001,12,1]]},"abstract":"<jats:p>Objective. Many children with human immunodeficiency virus-1 (HIV-1) have chronic problems with growth and nutrition, yet limited information is available to identify infected children at high risk for growth abnormalities. Using data from the prospective, multicenter P2C2 HIV study, we evaluated the relationships between maternal and infant clinical and laboratory factors and impaired growth in this cohort.<\/jats:p><jats:p>Methods. Children of HIV-1-infected women were enrolled prenatally or within the first 28 days of life. Failure to thrive (FTT) was defined as an age- and sex-adjusted weight z score \u2264\u22122.0 SD. Maternal baseline covariates included age, race, illicit drug use, zidovudine use, CD4+ T-cell count, and smoking. Infant baseline predictors included sex, race, CD4+ T-cell count, Centers for Disease Control stage, HIV-1 RNA, antiretroviral therapy, pneumonia, heart rate, cytomegalovirus, and Epstein-Barr virus infection status.<\/jats:p><jats:p>Results. The study cohort included 92 HIV-1-infected and 439 uninfected children. Infected children had a lower mean gestational age, but birth weights, lengths, and head circumferences in the 2 groups were similar. Mothers of growth-delayed infants were more likely to have smoked tobacco and used illicit drugs during pregnancy. In repeated-measures analyses of weight and length or height z scores, the means of the HIV-1-infected group were significantly lower at 6 months of age (P &amp;lt; .001) and remained lower throughout the first 5 years of life. In a multivariable Cox regression analysis, FTT was associated with a history of pneumonia (relative risk [RR] = 8.78; 95% confidence interval [CI]: 3.59\u201321.44), maternal use of cocaine, crack, or heroin during pregnancy (RR = 3.17; 95% CI: 1.51\u20136.66), infant CD4+ T-cell count z score (RR = 2.13 per 1 SD decrease; 95% CI: 1.25\u20133.57), and any antiretroviral therapy by 3 months of age (RR = 2.77; 95% CI: 1.16\u20136.65). After adjustment for pneumonia and antiretroviral therapy, HIV-1 RNA load remained associated with FTT in the subset of children whose serum was available for viral load analysis.<\/jats:p><jats:p>Conclusion. Clinical and laboratory factors associated with FTT among HIV-1-infected children include history of pneumonia, maternal illicit drug use during pregnancy, lower infant CD4+ T-cell count, exposure to antiretroviral therapy by 3 months of age (non-protease inhibitor), and HIV-1 RNA viral load.<\/jats:p>","DOI":"10.1542\/peds.108.6.1287","type":"journal-article","created":{"date-parts":[[2004,8,13]],"date-time":"2004-08-13T23:55:51Z","timestamp":1092441351000},"page":"1287-1296","source":"Crossref","is-referenced-by-count":46,"title":["Maternal and Infant Factors Associated With Failure to Thrive in Children With Vertically Transmitted Human Immunodeficiency Virus-1 Infection: The Prospective, P2C2 Human Immunodeficiency Virus Multicenter Study"],"prefix":"10.1542","volume":"108","author":[{"given":"Tracie L.","family":"Miller","sequence":"first","affiliation":[{"name":"Division of Pediatric Gastroenterology and Nutrition, University of Rochester Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirk A.","family":"Easley","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Epidemiology, the Cleveland Clinic Foundation, Cleveland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weihong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Epidemiology, the Cleveland Clinic Foundation, Cleveland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. John","family":"Orav","sequence":"additional","affiliation":[{"name":"Department of Medicine, Brigham and Women\u2019s Hospital, Boston"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis M.","family":"Bier","sequence":"additional","affiliation":[{"name":"Children\u2019s Nutrition Research Center, Texas Children\u2019s Hospital, Houston"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Luder","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Mount Sinai School of Medicine, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Ting","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Mount Sinai School of Medicine, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William T.","family":"Shearer","sequence":"additional","affiliation":[{"name":"Baylor College of Medicine, Department of Pediatrics, Division of Allergy and Immunology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge Humberto","family":"Vargas","sequence":"additional","affiliation":[{"name":"UCLA Center for the Health Sciences, Los Angeles"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven E.","family":"Lipshultz","sequence":"additional","affiliation":[{"name":"Division of Pediatric Cardiology, University of Rochester Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"for the Pediatric Pulmonary and Cardiovascular Complications of Vertically Transmitted HIV Infection (P2C2 HIV) Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"National Heart, Lung, and Blood Institute, Bethesda, MD","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"417","published-online":{"date-parts":[[2001,12,1]]},"reference":[{"key":"2021121003503397700_R1","doi-asserted-by":"crossref","unstructured":"Miller TL, Evans SJ, Orav EJ, McIntosh K, Winter HS. Growth and body composition in children infected with the human immunodeficiency virus-1. Am J Clin Nutr.1993;57:588\u2013592","DOI":"10.1093\/ajcn\/57.4.588"},{"key":"2021121003503397700_R2","doi-asserted-by":"crossref","unstructured":"Arpadi SM, Horlick MN, Wang J, Cuff P, Bamji M, Kotler DP. Body composition in prepubertal children with human immunodeficiency virus type 1 infection. Arch Pediatr Adolesc Med.1998;152:688\u2013693","DOI":"10.1001\/archpedi.152.7.688"},{"key":"2021121003503397700_R3","doi-asserted-by":"crossref","unstructured":"Saavedra JM, Henderson RA, Perman JA, Hotton N, Livingston RA, Yolken RH. Longitudinal assessment of growth in children born to mothers with human immunodeficiency virus infection. Arch Pediatr Adolesc Med.1995;149:497\u2013502","DOI":"10.1001\/archpedi.1995.02170180027004"},{"key":"2021121003503397700_R4","doi-asserted-by":"crossref","unstructured":"Moye J, Rich KC, Kalish LA, et al. Natural history of somatic growth in infants born to women infected by human immunodeficiency virus. J Pediatr.1996;128:58\u201369","DOI":"10.1016\/S0022-3476(96)70428-6"},{"key":"2021121003503397700_R5","doi-asserted-by":"crossref","unstructured":"McKinney RE, Robertson RW, and the Duke Pediatric AIDS Clinical Trials Unit. Effect of human immunodeficiency virus infection on the growth of young children. J Pediatr.1993;123:579\u2013582","DOI":"10.1016\/S0022-3476(05)80955-2"},{"key":"2021121003503397700_R6","doi-asserted-by":"crossref","unstructured":"Miller, TL, Awnetwant EL, Evans S, Morris VM, Vazquez IM. Gastrostomy tube supplementation for HIV-infected children. Pediatrics.1995;96:696\u2013702","DOI":"10.1542\/peds.96.4.696"},{"key":"2021121003503397700_R7","doi-asserted-by":"crossref","unstructured":"Miller TL, Evans SE, Vasquez I, Orav EJ. Dietary intake is an important predictor of nutritional status in HIV-infected children. Pediatr Res.1997;41:85A","DOI":"10.1203\/00006450-199704001-00517"},{"key":"2021121003503397700_R8","doi-asserted-by":"crossref","unstructured":"Henderson RA, Talusan K, Hutton N, Yolken RH, Caballero B. Resting energy expenditure and body composition in children with HIV infection. J Acquir Immune Defic Syndr.1998;19:150\u2013157","DOI":"10.1097\/00042560-199810010-00008"},{"key":"2021121003503397700_R9","doi-asserted-by":"crossref","unstructured":"Hommes MJT, Romijn JA, Endert E, Sauerwein HP. Resting energy expenditure and substrate oxidation in human immunodeficiency virus (HIV)-infected asymptomatic men: HIV affects host metabolism in the early asymptomatic stage. Am J Clin Nutr.1991;54:311\u2013315","DOI":"10.1093\/ajcn\/54.2.311"},{"key":"2021121003503397700_R10","doi-asserted-by":"crossref","unstructured":"Suttmann U, Ockenga L, Hoogestraat L, et al. Resting energy expenditure and weight loss in human immunodeficiency virus-infected patients. Metabolism.1993;42:1173\u20131179","DOI":"10.1016\/0026-0495(93)90277-U"},{"key":"2021121003503397700_R11","doi-asserted-by":"crossref","unstructured":"Miller TL, Orav EJ, Martin SR, et al. Malnutrition and carbohydrate malabsorption in children with vertically transmitted human immunodeficiency virus-1 infection. Gastroenterology.1991;100:1296\u20131302","DOI":"10.1016\/0016-5085(91)70016-Q"},{"key":"2021121003503397700_R12","doi-asserted-by":"crossref","unstructured":"Yolken RH, Hart W, Oung I, Schiff C, Greenson J, Perman JA. Gastrointestinal dysfunction and disaccharide intolerance in children infected with human immunodeficiency virus. J Pediatr.1991;118:359\u2013363","DOI":"10.1016\/S0022-3476(05)82147-X"},{"key":"2021121003503397700_R13","doi-asserted-by":"crossref","unstructured":"The P2C2 HIV Study Group. The pediatric pulmonary and cardiovascular complications of vertically transmitted human immunodeficiency virus (P2C2 HIV) infection study: design and methods. J Clin Epidemiol.1996;49:1285\u20131294","DOI":"10.1016\/S0895-4356(96)00230-2"},{"key":"2021121003503397700_R14","doi-asserted-by":"crossref","unstructured":"Hollinger F, Bremer J, Myers L, Gold J, McQuay L. The NIH\/NIAID\/DAIDS\/ACTG Virology Laboratories. Standardization of sensitive human immunodeficiency virus coculture procedures and establishment of a multicenter quality assurance program for the AIDS Clinical Trials Group. J Clin Microbiol.1992;30:1787\u20131794","DOI":"10.1128\/jcm.30.7.1787-1794.1992"},{"key":"2021121003503397700_R15","unstructured":"Centers for Disease Control and Prevention. Revised classification system for human immunodeficiency syndrome in children less than 13 years of age. MMWR Morb Mortal Wkly Rep.1994;43:1\u201310"},{"key":"2021121003503397700_R16","unstructured":"Mofenson LM, Bethel J, Moye J, Flyer P, Nugent R for the National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group. Effect of intravenous immunoglobulin (IVIG) on CD4+ lymphocyte decline in HIV-infected children in a clinical trial of IVIG infection prophylaxis. J Acquir Immune Defic Syndr.1993;6:1103\u20131113"},{"key":"2021121003503397700_R17","doi-asserted-by":"crossref","unstructured":"Shearer WT, Quinn TC, LaRussa P, et al. Viral load and disease progression in infants infected with human immunodeficiency virus type 1. N Engl J Med.1997;336:1337\u20131342","DOI":"10.1056\/NEJM199705083361901"},{"key":"2021121003503397700_R18","doi-asserted-by":"crossref","unstructured":"Rusconi F, Castagneto M, Gagliardi L, et al. Reference values for respiratory rate in the first three years of life. Pediatrics.1994;94:350\u2013355","DOI":"10.1542\/peds.94.3.350"},{"key":"2021121003503397700_R19","doi-asserted-by":"crossref","unstructured":"Shearer WT, Lipshultz SE, Easley KA, et al. Alterations in cardiac and pulmonary function in pediatric rapid human immunodeficiency virus type 1 disease progressors. Pediatrics.2000;105(1):. Available at: www.pediatrics.org\/cgi\/content\/full\/105\/1\/e9","DOI":"10.1542\/peds.105.1.e9"},{"key":"2021121003503397700_R20","doi-asserted-by":"crossref","unstructured":"Kovacs A, Schluchter M, Easley K, et al. Cytomegalovirus infection and HIV-1 disease progression in infants born to HIV-1-infected women. N Engl J Med.1999;341:77\u201384","DOI":"10.1056\/NEJM199907083410203"},{"key":"2021121003503397700_R21","doi-asserted-by":"crossref","unstructured":"Jenson H, McIntosh K, Pitt J, et al. Natural history of primary Epstein-Barr virus infection in children of mothers infected with human immunodeficiency virus type-1. J Infect Dis.1999;179:1395\u20131404","DOI":"10.1086\/314764"},{"key":"2021121003503397700_R22","doi-asserted-by":"crossref","unstructured":"Kattan M, Platzker A, Mellins RD, et al for the P2C2 HIV Study Group. Respiratory diseases in the first year of life in children born to HIV-1-infected women. Pediatr Pulmonol.2001;31:267\u2013276","DOI":"10.1002\/ppul.1038"},{"key":"2021121003503397700_R23","unstructured":"Lohman TG, Roche AF, Marttorell R. Anthropometric Standardization Manual. Champaign, IL: Human Kinetics; 1988"},{"key":"2021121003503397700_R24","unstructured":"ANTHRO Software for Calculating Pediatric Anthropometry, Version 1.01. Atlanta, GA: Centers for Disease Control and Prevention; 1990"},{"key":"2021121003503397700_R25","doi-asserted-by":"crossref","unstructured":"Babson SG, Benda GI. Growth graphs for the clinical assessment of infants of varying gestational age. J Pediatr.1976;89:814\u2013820","DOI":"10.1016\/S0022-3476(76)80815-3"},{"key":"2021121003503397700_R26","doi-asserted-by":"crossref","unstructured":"Gallo RC, Salahuddin SZ, Popovic M, et al. Frequency, detection, and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science.1984;124:500\u2013503","DOI":"10.1126\/science.6200936"},{"key":"2021121003503397700_R27","doi-asserted-by":"crossref","unstructured":"Barre-Sinousi F, Chermann JC, Fey F, et al. Isolation of T-cell lymphotrophic retrovirus from a patient at risk for AIDS. Science.1983;220:868\u2013871","DOI":"10.1126\/science.6189183"},{"key":"2021121003503397700_R28","doi-asserted-by":"crossref","unstructured":"Serwadda D, Mugerwa RD, Sewankambo NK, et al. Slim disease: a new disease in Uganda and its association with HTLV-III infection. Lancet.1985;2:849\u2013852","DOI":"10.1016\/S0140-6736(85)90122-9"},{"key":"2021121003503397700_R29","unstructured":"Carey VJ, Yong F, Frenkel L, McKinney R. Enhancing the prognostic value of bodily growth histories in HIV-positive pediatric cohorts [abstract]. Int Conf AIDS.1996;(July 7\u201312)11:134"},{"key":"2021121003503397700_R30","doi-asserted-by":"crossref","unstructured":"Missmer S, Speigelman D, Gorbach SL, Miller TL. Predictors of change in the functional status of children with human immunodeficiency virus infection. Pediatrics.2000;106(2):. Available at: http:\/\/www.pediatrics.org\/cgi\/content\/full\/106\/2\/e24","DOI":"10.1542\/peds.106.2.e24"},{"key":"2021121003503397700_R31","doi-asserted-by":"crossref","unstructured":"Money J. The syndrome of abuse dwarfism (psychosocial dwarfism or reversible hyposomatotropism). Am J Dis Child.1977;131:508\u2013513","DOI":"10.1001\/archpedi.1977.02120180022002"},{"key":"2021121003503397700_R32","doi-asserted-by":"crossref","unstructured":"Boulton TJ, Smith R, Single T. Psychosocial growth failure: a positive response to growth hormone and placebo. Acta Paediatr.1992;81:322\u2013325","DOI":"10.1111\/j.1651-2227.1992.tb12235.x"},{"key":"2021121003503397700_R33","unstructured":"Anonymous. Children whose mothers are infected with HIV. Communicable disease report. Commun Dis Rep CDR Wkly.1995;5:111"},{"key":"2021121003503397700_R34","doi-asserted-by":"crossref","unstructured":"Lifschitz MH, Wilson GS, Smith EO, Desmond MM. Fetal and postnatal growth of children born to narcotic-dependent women. Pediatrics.1983;102:686\u2013690","DOI":"10.1016\/S0022-3476(83)80234-0"},{"key":"2021121003503397700_R35","doi-asserted-by":"crossref","unstructured":"Salman EK, Haymond MW, Bayne E, et al. Protein and energy metabolism in prepubertal children with sickle cell anemia. Pediatr Res.1996;40:34\u201340","DOI":"10.1203\/00006450-199607000-00007"},{"key":"2021121003503397700_R36","doi-asserted-by":"crossref","unstructured":"Stallings VA, Zemel BS, Davies JC, Cronk CE, Charney EB. Energy expenditure of children and adolescents with severe disabilities: a cerebral palsy model. Am J Clin Nutr.1996;64:626\u2013634","DOI":"10.1093\/ajcn\/64.4.627"},{"key":"2021121003503397700_R37","doi-asserted-by":"crossref","unstructured":"Hankard R, Gottrand F, Turck D, Carpentier A, Romon M, Farriaux JP. Resting energy expenditure and energy substrate utilization in children with Duchenne muscular dystrophy. Pediatr Res.1996;40:29\u201333","DOI":"10.1203\/00006450-199607000-00006"},{"key":"2021121003503397700_R38","unstructured":"Alfaro MP, Siegel RM, Baker RC, Heubi JE. Resting energy expenditure and body composition in pediatric HIV infection. Pediatric AIDS and HIV Infection: Fetus Adolesc.1995;6:276\u2013280"},{"key":"2021121003503397700_R39","doi-asserted-by":"crossref","unstructured":"Arpadi SM, Cuff PA, Kotler DP, et al. Growth velocity, fat-free mass and energy intake are inversely related to viral load in HIV-infected children. J Nutr.2000;130:2498\u20132502","DOI":"10.1093\/jn\/130.10.2498"},{"key":"2021121003503397700_R40","doi-asserted-by":"crossref","unstructured":"Johann-Liang R, O\u2019Neill L, Cervia J, et al. Energy balance, viral burden, insulin-like growth factor-1, interleukin-6 and growth impairment in children infected with human immunodeficiency virus. AIDS.2000;14:683\u2013690","DOI":"10.1097\/00002030-200004140-00007"},{"key":"2021121003503397700_R41","doi-asserted-by":"crossref","unstructured":"Macallan DC, Noble C, Baldwin C, et al. Energy expenditure and wasting in human immunodeficiency virus infection. N Engl J Med.1995;333:83\u201388","DOI":"10.1056\/NEJM199507133330202"},{"key":"2021121003503397700_R42","doi-asserted-by":"crossref","unstructured":"Mhiri C, Baudrimont M, Bonne G, et al. Zidovudine myopathy: a distinctive disorder associated with mitochondrial dysfunction. Ann Neurol.1991;29:606\u2013614","DOI":"10.1002\/ana.410290607"},{"key":"2021121003503397700_R43","doi-asserted-by":"crossref","unstructured":"Miller TL, Mawn BE, Orav EJ, et al. The effect of protease inhibitor therapy on growth and body composition in human immunodeficiency virus type 1-infected children. Pediatrics.2001;107(5):. Available at: http:\/\/www.pediatrics.org\/cgi\/content\/full\/107\/5\/e77","DOI":"10.1542\/peds.107.5.e77"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/108\/6\/1287\/1113311\/pe1201001287.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/108\/6\/1287\/1113311\/pe1201001287.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T05:31:23Z","timestamp":1682746283000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/108\/6\/1287\/63641\/Maternal-and-Infant-Factors-Associated-With"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,12,1]]},"references-count":43,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2001,12,1]]},"published-print":{"date-parts":[[2001,12,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.108.6.1287","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,12,1]]}}}